Antiviral Treatment for COVID-19: A Systematic Review
Journal of Pharmaceutical Research International,
Aim: In December 2019, there were reports of a new type of coronavirus that affects the different health systems of the world. We have carried out a systematic review of the possible antivirals studied that could be useful in this public health catastrophe.
Data Sources: A search strategy with MESH terms was performed in PubMed, Web of Science, and Scopus. Also, RCTs published in clinicaltrials.gov were reviewed. The databases were searched between April and June 2020.
Study Selection: We selected all Randomized Controlled Trials evaluating the effects of antivirals and 5 studies were included from a research database of 280 articles collected between. After removing duplicated articles, 43 were selected for review. Finally, 5 articles were eligible for full-text review and included in the article.
Results: Current randomized controlled trial data showed no clinical improvement in terms of mortality, need for oxygen support or need for intubation in patients who used antivirals versus those who did not. No clinical improvement was demonstrated. It was observed that there is difficulty in calculating clinical improvement, this large difference makes the eligible studies difficult to compare.
Conclusion: These predictors, however, need further work to validate reliability. More clinical trials involving antivirals are needed to observe a relationship between clinical improvement or mortality from SARS-CoV-19.
- Systematic review
- clinical improvement
How to Cite
Porta M. A dictionary of epidemiology. 5th ed. Oxford: Oxford University Press; 2008.
Yang HY, Duan GC. Zhonghua analysis of the epidemic factors for the Corona virus disease. 2020;54(0):E021. DOI: 10.3760/cma.j.cn112150-20200227-00196
Spychalski P, Błażyńska-Spychalska A, Kobiela J. Estimating case fatality rates of COVID-19. Lancet Infect Dis. 2020;20(7): 774-775. DOI: 10.1016/S1473-3099(20)30246-2
Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020; 382(10):929-936. DOI: 10.1056/NEJMoa2001191
Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252-256. DOI: 10.1136/thorax.2003.012658
Chen C, Zhang Y, Huang J, et al. Favipiravir versus arbidol for COVID-19: A randomized clinical trial. medRxiv; 2020. DOI: https://doi.org/10.1101/2020.03.17.2-0037432
Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: Results of a randomized clinical trial. medRxiv. (In press); 2020. DOI: https://doi.org/10.1101/2020.03.22.2-0040758
Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020; 382:1787-1799. DOI: 10.1056/NEJMoa2001282
Borba MGS, Val FFA, Sampaio VS, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) Infection A Randomized Clinical Trial. JAMA Network Open. 2020; 3(4):208857. DOI: 10.1001/jamanetworkopen.2020.8857
Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: A randomized, double-blind, placebo-controlled, multicentre trial. The Lancet. 2020;395(10236):1569-1578. DOI: 10.1016/S0140-6736(20)31022-9
Hung IFN, Lung KC, Tso EYK, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: An open-label, randomized, phase 2 trial. The Lancet. 2020;395:1695-1704. DOI: 10.1016/ S0140-6736(20)31042-4
Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 - preliminary report. N Engl J Med; 2020. DOI: 10.1056/NEJMoa2007764
Higgins JP, Altman DG, Gotzsche PC, et al. The cochrane collaboration's tool for assessing risk of bias in randomized trials. BMJ. 2011;343:5928. DOI: 10.1136/bmj.d5928
Liu W, Zhou P, Chen K, et al. Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis. Canadian Medical Association Journal. 2020;192(27):E734-E744. Doi: https://doi.org/10.1503/cmaj.200647
Guan GW, Gao L, Wang JW, et al. Exploring the mechanism of liver enzyme abnormalities in patients with Novel Coronavirus-infected pneumonia. Zhonghua Gan Zang Bing Za Zhi. 2020; 28(2):100-106. DOI: 10.3760/cma.j.issn.10073418.202-0.02.002
U.S. FOOD & DRUG Administraction [Internet]. California U.S. Food & Drug Administration. Remdesivir EUA Letter of Authorization. 2020;6 . [Accessed 10 July 2020]. Available:https://www.fda.gov/media/137564/download
Piscoya A, Ng-Sueng L, Parra del Riego A, et al. Efficacy and harms of remdesivir for the treatment of COVID-19: A systematic review and meta-analysis. medRxiv; 2020. DOI: https://doi.org/10.1101/2020.05.26.-20109595
Musa A, Pendi K, Hashemi A, et al. Remdesivir for the Treatment of COVID-19: A systematic review of the literature. West J Emerg Med. 2020;21(4). DOI: 10.5811/westjem.2020.5.47658
Yousefifard M, Zali A, Mohamed Ali K, et al. Antiviral therapy in the management of COVID-19: A systematic review on current evidence. 2020;8(1):45. DOI: https://doi.org/10.1111/ijcp.13557
Zhang JJY, Lee KS, Ang LW, Leo YS, Young BE. Risk factors of severe disease and efficacy of treatment in patients infected with COVID-19: A systematic review, meta-analysis, and meta-regression analysis. Clinical Infectious Diseases; 2020. DOI: 10.1093/cid/ciaa576
Chowdhury MS, Rathod J, Gernsheimer J. Rapid systematic review of clinical trials utilizing chloroquine and hydroxychloroquine as a Treatment for COVID-19. Acad Emerg Med. 2020;27(6): 493-504. DOI: 10.1111/acem.14005
Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy of chloroquine for the treatment of COVID-19. Crit Care. 2020; 57:279-283. DOI: https://doi.org/10.1016/j.jcrc.2020.0-3.005
Heidary F, Gharebaghi R. Ivermectin: A systematic review from antiviral effects to COVID-19 complementary regimen. J Antibiot; 2020. DOI: https://doi.org/10.1038/s41429-020-0336-z
Di Lorenzo G, Di Trolio R, Kozlakidis Z, et al. COVID 19 therapies and anti-cancer drugs: A systematic review of recent literature. Crit Rev Oncol Hematol. 2020; 152:102991. DOI: 10.1016/j.critrevonc.2020.102991
Abstract View: 228 times
PDF Download: 147 times